Status: Recruiting
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent advanced solid tumors who have exhausted standard treatment options.
Participants needed: 230
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Nested Therapeutics, IncUpdated: Apr 20, 2026Locations: 23
Eligibility criteria
Subjects must be ≥18 years old (or of legal age of consent in the country in whi... [+16]
Conditions interfering with oral intake of NST-628 [+11]